|
|
Vaccine Detail
|
Adenovirus RSV-TK |
| Vaccine Information |
- Vaccine Name: Adenovirus RSV-TK
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007207
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- UL97
gene engineering:
- Type: Recombinant protein preparation
- Description: (He et al., 1997)
- Detailed Gene Information: Click Here.
- Description: A gene viral vector complex comprised of a replication-defective adenovirus and a herpes simplex virus thymidine kinase gene that activates ganciclovir, causing inhibition of DNA synthesis and apoptosis. This vaccine has been used in patients with cutaneous metastatic malignant melanoma. (Morris et al., 2000; NCIT_C2545).
|
| Host Response |
|
|
| References |
He et al., 1997: He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. Journal of virology. 1997; 71(1); 405-411. [PubMed: 8985364].
Morris et al., 2000: Morris JC, Ramsey WJ, Wildner O, Muslow HA, Aguilar-Cordova E, Blaese RM. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Human gene therapy. 2000; 11(3); 487-503. [PubMed: 10697123].
NCIT_C2545: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2545]
|
|
